TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29126203

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) with radiation therapy and concurrent/adjuvant temozolomide
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (radiation therapy with concurrent and adjuvant temozolomide without everolimus)
Number of subjects: 171
Study: 26714774

Group type: EXPERIMENTAL
Intervention: n‐3FA lovaza 4 g
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: raloxifene 60 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: raloxifene 30 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: lovaza 4 g plus raloxifene 30 mg
Number of subjects: 266

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 266
Study: 24661672

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (RT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 136
Study: 22908115

Group type: EXPERIMENTAL
Intervention: Milk fortified with 300 IU of vitamin D(3) (n = 143)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Unfortified regular milk (control; n = 104)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 247
Study: 19697119

Group type: EXPERIMENTAL
Intervention: Computerized Attention Training (CAT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 19087949

Group type: EXPERIMENTAL
Intervention: Happy Ending (HE) smoking cessation program
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (44-page self-help booklet)
Number of subjects: 290
Study: 15885299

Group type: EXPERIMENTAL
Intervention: O'Brien‐Fleming stopping method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peto group sequential stopping method
Number of subjects: 0
Study: 14512132

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate 50-microg nasal spray
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride 180-mg tablets
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo topical solution
Number of subjects: 73
Study: 10098806

Group type: EXPERIMENTAL
Intervention: Striking a reinforced structure with a 4.54 kg sledge hammer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Striking a weighted truck tire with a 4.54 kg sledge hammer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Striking a reinforced structure with a 5.60 kg sledge hammer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Striking a weighted truck tire with a 5.60 kg sledge hammer
Number of subjects: 20
Study: 8901655

Group type: EXPERIMENTAL
Intervention: High-dose Integrelin (90 micrograms/kg bolus followed by 1.0 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-dose Integrelin (45 micrograms/kg bolus followed by 0.5 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 1809429

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) morphine
Number of subjects: 38

Group type: COMPARATOR
Intervention: p.r.n. intravenous morphine
Number of subjects: 38
Study: 6882604

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol (during treatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31444917

Group type: EXPERIMENTAL
Intervention: Poloxamer-based thermo-sensitive sol-gel instillation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Lubricant instillation (Control)
Number of subjects: 198
Study: 30989380

Group type: COMPARATOR
Intervention: Resting heart rate (RHR) > 80 bpm
Number of subjects: 16201

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (GRS) for RHR
Number of subjects: 16201

Group type: EXPERIMENTAL
Intervention: Higher resting heart rate
Number of subjects: 16201
Study: 28281052

Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit (night-use group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No night-use group (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit (after Day 30 for all patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit
Number of subjects: 40
Study: 27434918

Group type: EXPERIMENTAL
Intervention: Prosthesis group (RPD)
Number of subjects: 376

Group type: COMPARATOR
Intervention: No aid group
Number of subjects: 376
Study: 24841163

Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 320 μg once daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 μg two inhalations twice daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC)
Number of subjects: 150
Study: 22007656

Group type: EXPERIMENTAL
Intervention: Upper limb exercises followed by manual therapy (MT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Upper limb exercises alone
Number of subjects: 131
Study: 19707090

Group type: EXPERIMENTAL
Intervention: Personal digital assistant-based log with obesity decision support features
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Personal digital assistant-based log without obesity decision support features
Number of subjects: 1874
Study: 17312210

Group type: EXPERIMENTAL
Intervention: Sugammadex, 4 mg/kg IV (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Edrophonium, 1 mg/kg IV and atropine, 10 microg/kg IV (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmine, 70 microg/kg IV and glycopyrrolate, 14 microg/kg IV (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmine-glycopyrrolate group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sugammadex group
Number of subjects: 60
Study: 15802292

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA) infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline leg vascular resistance measurement
Number of subjects: 21
Study: 11782752

Group type: EXPERIMENTAL
Intervention: CarboMedics
Number of subjects: 485

Group type: COMPARATOR
Intervention: St Jude Medical
Number of subjects: 485
Study: 9852985

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 3200 pfu/dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 8500 pfu/dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 41,650 pfu/dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control pneumococcal polysaccharide vaccine
Number of subjects: 200
Study: 8184803

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control
Number of subjects: 919
Study: 3141301

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg tablet)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg injection)
Number of subjects: 93
Study: 31462695

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 28960777

Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: MR‐proADM
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: cystatin C
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 1853
Study: 28111051

Group type: EXPERIMENTAL
Intervention: Web-based interactive education platform
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Document education group
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2226
Study: 25639198

Group type: EXPERIMENTAL
Intervention: DISE plus MM (19 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MM only (20 patients)
Number of subjects: 39
Study: 23307675

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) introduced into the tunnels peri-operatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: No PRP introduced into the tunnels (Control)
Number of subjects: 50
Study: 21676232

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) in 28 fractions delivering 50.4 Gy to the breast and 64.4 Gy to the tumor bed by integrated boost
Number of subjects: 502

Group type: COMPARATOR
Intervention: Conventional Radiotherapy in 28 fractions to a dose of 50.4 Gy and consecutive boost in 8 fractions to a total dose of 66.4 Gy
Number of subjects: 502
Study: 18224474

Group type: EXPERIMENTAL
Intervention: Surgeon performed ultrasound (SUS)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Radiologist performed ultrasound (RUS)
Number of subjects: 218
Study: 16525138

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for a minimum of 52 weeks
Number of subjects: 648

Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily for a minimum of 52 weeks
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 648

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 648
Study: 14633754

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2% 5 ml h(‐1) for 55 h after infiltration with ropivacaine 0.5% 40 ml.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Systemic analgesia with continuous i.v. infusion of morphine plus ketorolac for 24 h followed by saline infusion for 55 h.
Number of subjects: 37
Study: 11602412

Group type: EXPERIMENTAL
Intervention: Computer-aided dosing
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Control group (expert physicians without algorithms)
Number of subjects: 1251
Study: 9580382

Group type: EXPERIMENTAL
Intervention: Aripiprazole (8 weeks of open‐label treatment)
Number of subjects: 15
Study: 8306022

Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall patient survival
Number of subjects: 40
Study: 2493798

Group type: EXPERIMENTAL
Intervention: Bain system
Number of subjects: 20

Group type: COMPARATOR
Intervention: ADE system
Number of subjects: 20
Study: 31912685

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy (RT) alone
Number of subjects: 316
Study: 31382965

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 28796940

Group type: EXPERIMENTAL
Intervention: Telephone-delivered depression care management (DCM)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 628
Study: 26656642

Group type: EXPERIMENTAL
Intervention: Donepezil (first dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline measures of CANTAB tests (PAL, PRM, CRT)
Number of subjects: 72
Study: 23490304

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy (BBCET)
Number of subjects: 196
Study: 21785369

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Reduced Work Hours (RWH)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Referents (Control)
Number of subjects: 177
Study: 19537033

Group type: EXPERIMENTAL
Intervention: Ulinastatin (4 x 10^6 U in 100 ml normal saline infused intravenously for 30 min since skin incision, with additional 2 x 10^6 U infused at a rate of 4-6 x 10^4 U x h(-1) until chest closure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (100 ml normal saline without ulinastatin)
Number of subjects: 36
Study: 16428534

Group type: EXPERIMENTAL
Intervention: J‐Tip with 0.25 mL of 1% buffered lidocaine (n = 57)
Number of subjects: 116

Group type: COMPARATOR
Intervention: EMLA with 2.5 g (n = 59)
Number of subjects: 116
Study: 14971232

Group type: EXPERIMENTAL
Intervention: Vaxem Hib
Number of subjects: 331

Group type: COMPARATOR
Intervention: HibTITER
Number of subjects: 331
Study: 11575224

Group type: EXPERIMENTAL
Intervention: Mercury or aneroid sphygmomanometer
Number of subjects: 3388

Group type: COMPARATOR
Intervention: SECURUS manometer
Number of subjects: 3388
Study: 9038285

Group type: COMPARATOR
Intervention: Listening to frequent low- or rare high-pitched tones (LIS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Selective auditory attention to deviants in one ear (ATTR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Selective auditory attention to deviants in the left ear (ATTL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Silent rest (REST)
Number of subjects: 17
Study: 8269798

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg 2 times/day for 12 weeks
Number of subjects: 12
Study: 31522180

Group type: EXPERIMENTAL
Intervention: Regional Citrate Anticoagulation (RCA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-Anticoagulation
Number of subjects: 64
Study: 30253689

Group type: EXPERIMENTAL
Intervention: Parental mental-health problems
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Child mental-health problems
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Families with at least one individual experiencing mental-health problems
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Use of parental support and/or psychological health-care services
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Families without mental-health problems
Number of subjects: 3164
Study: 29911379

Group type: EXPERIMENTAL
Intervention: Enoxaparin (once daily subcutaneous injections)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no anticoagulation)
Number of subjects: 50
Study: 26237831

Group type: EXPERIMENTAL
Intervention: Auricular pressing treatment using Semen Vaccariae on auricular points CO10, LO5, TF4, CO15, CO12, and CO13 for three treatment courses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 72
Study: 23769562

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin combined with cyclosporine A (CsA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) alone
Number of subjects: 76
Study: 21445364

Group type: COMPARATOR
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Ventilator-associated complications (VAC)
Number of subjects: 600
Study: 18343739

Group type: EXPERIMENTAL
Intervention: First-line polychemotherapy regimen including oxaliplatin or irinotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line therapy and/or crossover between first-line treatment arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 0
Study: 16911696

Group type: EXPERIMENTAL
Intervention: High dose vitamin K3 (n = 23); administered by i.v. infusion of 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by 20 mg i.m. twice daily for 2 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 42
Study: 12726869

Group type: EXPERIMENTAL
Intervention: STEP intervention (exercise counseling and prescription of an exercise training heart rate)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: STEP intervention
Number of subjects: 284

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 284
Study: 10985895

Group type: EXPERIMENTAL
Intervention: CCC (100 mg/m² of cisplatin, 300 mg/m² of cyclophosphamide, 300 mg/m² of carboplatin)
Number of subjects: 195

Group type: COMPARATOR
Intervention: CC (100 mg/m² of cisplatin, 600 mg/m² of cyclophosphamide)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CCC
Number of subjects: 195
Study: 9229324

Group type: EXPERIMENTAL
Intervention: 48-hour bimonthly LV5-FU bolus and infusion
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control arm of ongoing trials
Number of subjects: 5
Study: 1365656

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 16
Study: 6738143

Group type: EXPERIMENTAL
Intervention: Monthly feedback of individual performance ranked with that of peers (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group 2) receiving feedback in the second 6-month period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 1 (no feedback in the second 6-month period)
Number of subjects: 0
Study: 31276605

Group type: EXPERIMENTAL
Intervention: WWW-roadmap
Number of subjects: 128

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 128
Study: 29246755

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Older age group (9.9-13 years)
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Dark skin complexion
Number of subjects: 2251
Study: 26987997

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol Spiromax 160/4.5 mcg
Number of subjects: 574

Group type: COMPARATOR
Intervention: Budesonide-formoterol Turbuhaler 200/6 mcg
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol Spiromax
Number of subjects: 574

Group type: COMPARATOR
Intervention: Budesonide-formoterol Turbuhaler
Number of subjects: 574
Study: 24875654

Group type: EXPERIMENTAL
Intervention: TIP3-2 combined with medication (1-2 mg Estazolam nightly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication only (1-2 mg Estazolam nightly)
Number of subjects: 90
Study: 22367659

Group type: EXPERIMENTAL
Intervention: Sertindole 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20175658

Group type: EXPERIMENTAL
Intervention: Early full weight bearing protocol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (full weight bearing after 6 weeks)
Number of subjects: 14
Study: 18172414

Group type: EXPERIMENTAL
Intervention: Tango classes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exercise classes
Number of subjects: 19
Study: 15738315

Group type: EXPERIMENTAL
Intervention: Behavioral therapies for methamphetamine abuse
Number of subjects: 162
Study: 12518253

Group type: EXPERIMENTAL
Intervention: Insulin aspart, 0.05 U/kg-body-weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin lispro, 0.05 U/kg-body-weight
Number of subjects: 20
Study: 9689296

Group type: EXPERIMENTAL
Intervention: 7.5% aqueous sodium lauryl sulfate solution
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water‐ and untreated skin
Number of subjects: 17
Study: 8135026

Group type: EXPERIMENTAL
Intervention: Oropharyngeal gentamicin (40 mg, 4 times a day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (5% dextrose, 4 times a day)
Number of subjects: 67
Study: 2758972

Group type: EXPERIMENTAL
Intervention: Secobarbital 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secobarbital 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secobarbital (all doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1102569

Group type: EXPERIMENTAL
Intervention: Metiapine (maximum dose of 450 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorpromazine (maximum daily dose of 900 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metiapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 60
Study: 31721790

Group type: EXPERIMENTAL
Intervention: UB0316 (5 billion CFU each of L. salivarius UBLS22, L. casei UBLC42, L. plantarum UBLP40, L. acidophilus UBLA34, B. breve UBBr01, B. coagulans Unique IS2, and 100 mg fructo-oligosaccharides), twice-a-day for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 28877858

Group type: EXPERIMENTAL
Intervention: Submucosal turbinectomy with lateralization
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Submucosal electrocautery
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Laser cautery
Number of subjects: 109
Study: 25144793

Group type: EXPERIMENTAL
Intervention: nevirapine-based ART
Number of subjects: 99

Group type: COMPARATOR
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower 6-month gain in CD4%
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower 6-month gains in weight-for-age
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower 6-month gains in height-for-age
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower 6-month gains in weight-for-height
Number of subjects: 99
Study: 23499069

Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% injection (0.2 mL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Balanced salt solution injection (0.2 mL)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Trypan blue group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 22368359

Group type: EXPERIMENTAL
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable collagen membrane (GTRC)
Number of subjects: 10
Study: 19877219

Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil, and tacrolimus (modified therapy group)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Tacrolimus and steroids (standard therapy group)
Number of subjects: 157
Study: 17076857

Group type: EXPERIMENTAL
Intervention: Amicus (A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trima (T)
Number of subjects: 60
Study: 12679389

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG washout in patients with TPM1‐Asp175Asn
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG washout in LV segments
Number of subjects: 30